Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;10(9):2254-2266.
doi: 10.1016/j.jaip.2022.04.035. Epub 2022 May 10.

Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next

Kristen B Corey  1 , Grace Koo  1 , Elizabeth J Phillips  2
Affiliations
Review

Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next

Kristen B Corey et al. J Allergy Clin Immunol Pract. 2022 Sep.

Abstract

Just over 1 year following rollout of the first vaccines for coronavirus disease 2019, 572 million doses have been administered in the United States. Compared with the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the rarer the occurrence. Despite these adverse effects, there are few, if any, true contraindications to coronavirus disease 2019 vaccination and most individuals recover without further sequelae. This review provides guidance for the allergist/immunologist regarding appropriate next steps based on patient's known allergy history or adverse reaction after receipt of coronavirus disease 2019 vaccine to assist in safe global immunization.

Keywords: COVID-19; adverse effects; allergic reaction; anaphylaxis; vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Timeline of adverse reactions. The chart displays the time frame in which an individual is at highest risk of experiencing symptoms, with each of the adverse reactions discussed. It is important to note that TTS/VITT typically occurs within 1 to 2 weeks of vaccination, but the diagnostic criteria state that this may be considered for diagnosis up to 42 days after receipt of immunization. In addition, myocarditis and pericarditis may occur after first dose. SJS/TEN, Stevens-Johnson syndrome or toxic epidermal necrolysis; TTS, thrombosis with thrombocytopenia syndrome.
Figure 2
Figure 2
Guidance for exemptions. Examples of questions that may be asked of an allergist/immunologist in the evaluation of an individual with concerns about COVID-19 vaccination accompanied by proposed advice and solutions.
See this image and copyright information in PMC

References

    1. Randall T., Sam C., Tartar A., Murray P., Cannon C. More than 10.1 billion shots given: Covid-19 Tracker 2022. https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribu... Updated April 25, 2022. Accessed April 25, 2022.
    1. ClinicalTrials.gov A phase 1 study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA vaccine (mRNA-1644) and core-g28v2 60mer mRNA vaccine (mRNA-1644v2-Core) 2021. https://clinicaltrials.gov/ct2/show/NCT05001373 Updated September 30, 2021. Accessed October 29, 2021.
    1. ClinicalTrials.gov Safety, tolerability, and immunogenicity of Zika vaccine mRNA-1893 in healthy flavivirus seropositive and seronegative adults. 2021. https://clinicaltrials.gov/ct2/show/NCT04064905 Updated April 22, 2021. Accessed October 29, 2021.
    1. Miao L., Zhang Y., Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41. - PMC - PubMed
    1. Sahin U., Kariko K., Tureci O. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759–780. - PubMed

Publication types